Nipent (Pentostatin)

Pentostatin, the active ingredient in Nipent, is a purine analog (antimetabolite) presented as an injectable solution for intravenous use. It is employed in the treatment of certain lymphoid cancers, particularly in adult patients with hairy cell leukemia or chronic lymphocytic leukemia.

GNH USA supplies Nipent as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to European Union quality standards and provides regulatory‑approved batches for clinical use.

Pentostatin is used in hematologic malignancies that involve malignant B‑cell proliferation.

- Hairy cell leukemia: induces remission by targeting malignant B‑cells. - Chronic lymphocytic leukemia: reduces disease burden in patients refractory to other therapies. - Non‑Hodgkin lymphoma: may be employed as part of combination regimens for certain subtypes.

Pentostatin is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Fatigue: generalized tiredness during treatment cycles. - Fever and chills: often related to neutropenia. - Myelosuppression: decreased blood cell counts, especially neutrophils. - Infections: opportunistic bacterial, fungal or viral infections.

Serious or Rare Side Effects: - Severe neutropenia or pancytopenia: may lead to life‑threatening infections. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Hepatic dysfunction: elevated transaminases or bilirubin.

Pentostatin requires careful monitoring and specific handling precautions.

- Monitor blood counts: perform regular CBCs to detect myelosuppression early. - Assess infection risk: evaluate for signs of infection and consider prophylactic antibiotics when indicated. - Renal function: adjust use in patients with impaired clearance. - Hepatic function: monitor liver enzymes during therapy. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Pentostatin can interact with other agents that affect bone marrow or immune function.

Major Interactions (Avoid): - Concurrent myelosuppressive chemotherapy: markedly increases risk of severe bone‑marrow suppression. - Live attenuated vaccines: may cause uncontrolled infection due to immunosuppression. - High‑dose radiation therapy: potentiates hematologic toxicity.

Moderate Interactions (Monitor Closely): - Allopurinol: may enhance toxicity by affecting purine metabolism. - Antifungal azoles (e.g., fluconazole): can increase pentostatin plasma levels. - Antiviral agents (e.g., acyclovir): monitor renal function when co‑administered.